3-FEA

hypertension, coronary artery disease, arrhythmias, cerebrovascular disease, Takotsubo cardiomyopathy history

3-FEA's norepinephrine and dopamine releasing activity produces acute sympathetic cardiovascular stress. Gresnigt et al. 2022 found severe CV complications in 40% of 4-FA mono-intoxication ED presentations. Pre-existing cardiovascular conditions amplify risk to life-threatening levels.

epilepsy, history of seizures, conditions lowering seizure threshold

Catecholamine release and CNS stimulation reduce seizure threshold. Risk is dose-dependent and elevated with repeated dosing, sleep deprivation, or concurrent proconvulsant agents.

schizophrenia, bipolar disorder, schizoaffective disorder, psychotic episode history

Amphetamine-class stimulants potentiate mesolimbic and mesocortical dopamine signaling, which can trigger psychotic breaks or manic episodes in predisposed individuals. The serotonin component may partially modulate this risk but does not eliminate it.

If 3-FEA undergoes hepatic CYP-mediated metabolism (predicted by class analogy with amphetamines), hepatic impairment would reduce clearance, prolong plasma exposure, and potentially intensify/extend effects and toxicity.

No 3-FEA-specific reproductive toxicity data exist. Amphetamine-class compounds cross the placental barrier and produce vasoconstriction reducing placental perfusion. Neonatal withdrawal syndrome documented for amphetamines. Risk classification inferred entirely from class.

Concurrent use or use within 14 days of irreversible MAOI discontinuation (phenelzine, tranylcypromine) or high-dose reversible MAOIs (moclobemide). 3-FEA forces massive monoamine release; MAO inhibition prevents metabolic degradation, causing lethal serotonin/NE/DA accumulation.

Tramadol acts as an SNRI via active metabolites; combined with 3-FEA's SERT-mediated serotonin release, this produces potentially fatal serotonin accumulation. Listed as lethal risk in existing interaction data.

SSRIs, SNRIs, lithium, triptans, St. John's Wort

Co-administration with drugs that elevate synaptic serotonin (SSRIs, SNRIs, lithium, triptans) creates additive serotonergic load. While individual risk depends on specific agent and dose, the combination significantly elevates serotonin syndrome probability.